摘要
目的探讨血清人附睾蛋白4(HE4)和糖类抗原125(CA125)鉴别诊断卵巢癌与卵巢良性肿瘤的临床价值。方法选取卵巢癌患者38例(病例组)和卵巢良性肿瘤42例(对照组)为研究对象。采用酶联免疫吸附法(ELISA)检测2组患者血清HE4、CA125水平,并采用受试者工作特征曲线(ROC)评估血清HE4、CA125鉴别诊断卵巢癌和卵巢良性肿瘤的敏感性、特异性、阳性预测值、阴性预测值及ROC曲线下面积(AUC)。结果病例组血清HE4、CA125水平分别显著高于对照组(P<0.05)。以血清HE4为参考鉴别诊断卵巢癌与卵巢良性肿瘤的敏感性和特异性分别为74.4%和71.9%,阳性预测值和阴性预测值分别为5.41(95%CI:2.88-10.36)和0.56(0.21-0.78),AUC为0.87(95%CI:0.80-0.95);以血清CA125为参考鉴别诊断卵巢癌与卵巢良性肿瘤的敏感性和特异性分别为80.6%和75.4%,阳性预测值和阴性预测值分别为6.23(95%CI:3.12-13.64)和0.48(0.19-0.718),AUC为0.94(95%CI:0.89-0.99)。结论 HE4和CA125可作为鉴别诊断卵巢癌和卵巢良性肿瘤的血清学标志物。
Objective To evaluate the clinical values of serum HE4 and CA125 as biomarkers for diagnosis of ovarian cancer and benign ovarian tumors. Methods 38 patients with ovarian cancer（ Case Group）and 42 patients with benign ovarian tumors（ Control Group） were recruited in this study. The serum level of HE4 and CA125 were tested by ELISA assay. The diagnostic sensitivity,specificity,positive likely hood ratio,negative likely hood ratio and area under the ROC curve for ovarian cancer and benign ovarian tumors were diagnosed by ROC curve. Results The serum level of HE4 and CA125 in the Case Group were significant higher than that in the Control Group（ P〈0. 05）. The diagnostic sensitivity,specificity,positive likely hood ratio,negative likely hood ratio and area under the ROC curve were 74. 4%,71. 9%,5. 41（ 95% CI： 2. 88- 10. 36）,0. 56（ 0. 21- 0. 78） and 0. 87（ 95% CI： 0. 80- 0. 95） for serum HE4,respectively. And 80. 6%,75. 4%,6. 23（ 95% CI： 3. 12- 13. 64）,0. 48（ 0. 19- 0. 718） and 0. 94（ 95%CI： 0. 89- 0. 99） for serum CA125,respectively. Conclusion The serum HE4 and CA125 can be biomarkers for diagnosis of ovarian cancer and benign ovarian tumors.
出处
《湖北民族学院学报（医学版）》
2017年第1期28-30,共3页
Journal of Hubei Minzu University(Medical Edition)
